Sammaritano L R, Gharavi A E, Soberano C, Levy R A, Lockshin M D
Division of Rheumatic Diseases, Hospital for Special Surgery-Cornell University Medical Center, New York, New York 10021.
J Clin Immunol. 1992 Jan;12(1):27-35. doi: 10.1007/BF00918270.
We evaluated the interaction of antiphospholipid antibodies (aPL) with placental anticoagulant protein I (PAP I), a calcium-dependent phospholipid binding protein which may act as a natural anticoagulant. Clotting assays showed additive prolongation of clotting times with aPL and PAP I. ELISA and vesicle phospholipid binding studies showed PAP I inhibition of aPL binding to phospholipid but no inhibition of PAP I-phospholipid binding by aPL. aPL and PAP I interact additively in anticoagulant activity in in vitro clotting systems and compete for phospholipid in ELISA system. These data support the hypotheses that aPL and PAP I may recognize similar phospholipid epitopes and that in vivo interaction may occur.
我们评估了抗磷脂抗体(aPL)与胎盘抗凝蛋白I(PAP I)的相互作用,PAP I是一种钙依赖性磷脂结合蛋白,可能作为一种天然抗凝剂。凝血试验显示,aPL和PAP I可使凝血时间呈累加延长。酶联免疫吸附测定(ELISA)和囊泡磷脂结合研究表明,PAP I可抑制aPL与磷脂的结合,但aPL不会抑制PAP I与磷脂的结合。在体外凝血系统中,aPL和PAP I在抗凝活性方面呈累加相互作用,在ELISA系统中则竞争磷脂。这些数据支持以下假设:aPL和PAP I可能识别相似的磷脂表位,并且在体内可能发生相互作用。